ASA TABLET (DELAYED-RELEASE)

Land: Kanada

Sprache: Englisch

Quelle: Health Canada

Wirkstoff:

ACETYLSALICYLIC ACID

Verfügbar ab:

PHARMASCIENCE INC

ATC-Code:

B01AC06

INN (Internationale Bezeichnung):

ACETYLSALICYLIC ACID

Dosierung:

81MG

Darreichungsform:

TABLET (DELAYED-RELEASE)

Zusammensetzung:

ACETYLSALICYLIC ACID 81MG

Verabreichungsweg:

ORAL

Einheiten im Paket:

24/30/100/120/150/180/225/250/255/1000

Verschreibungstyp:

OTC

Therapiebereich:

SALICYLATES

Produktbesonderheiten:

Active ingredient group (AIG) number: 0101169013; AHFS:

Berechtigungsstatus:

APPROVED

Berechtigungsdatum:

2014-11-20

Fachinformation

PRODUCT MONOGRAPH
ASA
Acetylsalicylic Acid Delayed-release Tablets USP
81 mg
Platelet aggregation inhibitor
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montréal, Québec
H4P 2T4
DATE OF REVISION:
May 30, 2022
www.pharmascience.com
SUBMISSION CONTROL NUMBER: 263622
_Product Monograph - ASA _
_ _
_ _
_ _
_Page 2 of 39 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................6
DRUG INTERACTIONS
....................................................................................................7
DOSAGE AND ADMINISTRATION
................................................................................9
OVERDOSAGE
................................................................................................................10
ACTION AND CLINICAL PHARMACOLOGY
............................................................11
STORAGE AND STABILITY
..........................................................................................12
SPECIAL HANDLING INSTRUCTIONS
.......................................................................12
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................13
PART II : SCIENTIFIC INFORMATION
...............................................................................14
PHARMACEUTICAL INFORMATION
..........................................................................14
CLINICAL TRIALS
....................................................